Rheumatoid Arthritis (RA) Therapy Area Report

Published: February 16, 2022 |

Lumanity | 65 Pages | Delivery time: 1-2 business days

Price

Description
Table of Contents

Add to Compare

Our latest report provides insights into the Rheumatoid Arthritis (RA) online landscape, from the perspective of multiple stakeholders, and offers an evaluation of the extensive competitive landscape in this space. It identifies and provides a detailed overview of present and developing patient needs, hot topics of conversation amongst physicians, and prominent digital opinion leaders. Additionally, the report will help assess how pharma companies are utilising social media to engage in RA discussions, and understand ways in which to best connect with and support key customers.

Introduction

Executive Summary, Methodology and Background

RA Social Media Landscape Overview

Social Media Conversation Architecture

The Patient Voice

Patient Audiences in RA
Key Topics of Patient Conversation
Disease Experiences:
- Diagnosis
- Unmet Needs in Young Adult / Pregnant Women
- Mental Health Impact
- COVID-19 and RA
Treatment Experiences:
- Brand Discussion
- Treatment Switching
- Safety Discussions
- JAKiSafety Discussion and Key Questions Asked
- Mode of Administration
- Remission Discussion
Summary and Opportunities from the Patient Conversation

Clinical Conversations

Physician Online Audiences
Key Topics of Physician Conversation
Physician Views on JAKiSafety
Key Conference SoV
EULAR 2021 Discussions
ACR 2021 Discussions
Top Digital Opinion Leaders in RA
Summary and Opportunities from the Physician Conversation

Competitive Intelligence

Summary of Key Company Online Performance
Key Company Social Media Presence
Company Social Media Activity Overview:
- UCB
- Galapagos
- BMS
- Amgen
- Pfizer
- Sanofi
- AbbVie
- Genentech
- Janssen
- Eli Lilly
Summary and Opportunities from the Pharma Conversation